BiotechTube
Focal Biosciences

Focal Biosciences

Basel, Switzerland· Est.
focalbiosciences.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4.5M

Overview

Focal Biosciences is an early-stage biotech leveraging its proprietary CFC (Chromatin Fingerprint for Cell state)-Platform to discover drugs that reprogram diseased cells. The company integrates AI, machine learning, and tissue-mimicking disease models to target the chromatin landscape, with an immediate focus on fibrotic diseases and a broader vision for age-related chronic conditions. As a private, pre-revenue company likely in the pre-clinical stage, it is seeking collaborations and investment to advance its transformative approach to drug discovery.

OncologyImmunologyFibrosis

Technology Platform

CFC (Chromatin Fingerprint for Cell state)-Platform: An AI-enhanced platform that maps chromatin states to create cellular fingerprints, enabling the discovery of drugs that reprogram diseased cells back to a healthier state. Utilizes tissue-mimicking disease models and machine learning for target identification and validation.

Funding History

1
Total raised:$4.5M
Seed$4.5M

Opportunities

The antifibrotic and broader chronic disease market is large and lacks curative therapies, creating a significant opportunity for a disease-modifying approach.
The platform's applicability to multiple age-related diseases (cancer, senescence) allows for pipeline expansion and potential partnerships across therapeutic areas.
The growing investor interest in longevity and epigenetic reprogramming provides a favorable funding environment.

Risk Factors

The core scientific approach of pharmacologically reprogramming chromatin is highly novel and faces significant technical hurdles in identifying safe and effective drugs.
As an early-stage, pre-clinical company with no disclosed lead assets, it carries high development and funding attrition risk.
It operates in a competitive landscape of epigenetic drug discovery against more established players.

Competitive Landscape

Focal competes in the epigenetic drug discovery space with companies targeting chromatin modifiers (e.g., histone deacetylase inhibitors, EZH2 inhibitors) and a growing number of biotechs focused on cellular reprogramming and senescence. Its differentiation lies in its AI-driven 'chromatin fingerprint' approach for target discovery, but it must demonstrate superiority over competitors with more advanced clinical pipelines.

More companies in Cell & Gene Therapy →More companies in Switzerland →